Company deal history
Eli Lilly acquisitions since 2017
Eli Lilly has become one of pharma's busiest buyers, adding cancer, gene therapy, immunology and neuroscience programs as its obesity drugs took off. We found 24 deals since 2017. The largest with an announced price was Loxo Oncology at $8B.
- Deals found
- 24
- Stated value
- $27.2B
- Paywalls
- 0
20267 deals
Undisclosed
Immune drugs including for Graves' disease, price including milestones
Aug 2026 · Announced, not yet closed · BioPharma Dive ↗
$2.9B
Curevo, LimmaTech and Vaccine Company
Three vaccine companies, combined price including milestones
May 2026 · BioPharma Dive ↗
$4Breported
$300M
Kelonia Therapeutics
In-body cell therapy for multiple myeloma, price including milestones
Apr 2026 · Announced, not yet closed · BioPharma Dive ↗
$7B
$1.18B
Undisclosed
20254 deals
$1B
$1B
$2.5B
Undisclosed
20242 deals
Undisclosed
Undisclosed
20235 deals
$1.4B
Undisclosed
$1.9B
Undisclosed
Undisclosed
20221 deal
Undisclosed
20211 deal
Undisclosed
20201 deal
Undisclosed
20191 deal
$8B
20181 deal
Undisclosed
20171 deal
Undisclosed
These are the deals we could confirm from free public sources, last checked Nov 10, 2026, so small deals may be missing. New deals are added from our daily coverage. "Undisclosed" also covers deals where we couldn't confirm a price. Stated value adds up announced purchase prices only and leaves out undisclosed and reported prices and sales. Dates are when a deal closed, or when it was announced if it hasn't closed yet.